Mpox Biology, Outcome, Transmission and Epidemiology - Tracking the Immune Response After mpoX vaCcination (MBOTE-TRAXX): Clinical Study to Monitor the Immunological Response Following Mpox Vaccination in the City of Kinshasa, Democratic Republic of the Congo
Saves the questions and what to expect into your notes, next to the visit they belong to.
Keep this study
Lead
Institute of Tropical Medicine, Belgium
With
Institut National de Recherche Biomedicale (INRB)
Programme Elargi de Vaccination de République Démocratique du Congo
National Institute of Public Health of the Democratic Republic of the Congo
The study Mbote-TRAXX evaluates humoral and cellular immune responses in individuals vaccinated against mpox with the MVA-BN or LC16m8 vaccine administered as part of a routine mpox vaccination campaign in Kinshasa, Democratic Republic of the Congo (DRC). Participants will be followed up at multiple time points after vaccination in order to assess the kinetics and durability of the immune response. It is planned to include approximately 150 participants vaccinated with MVA-BN and 150 participants vaccinated with LC16m8. Participants will be followed up in the clinical trial for a period of 24 months with 6 visits: visit 1 (day 0), visit 2 (day 0 + 28 days), visit 3 (day 0 + 59 days), visit 4 (day 0 + 8 months), visit 5 (day 0 + 16 months) and visit 6 (day 0 + 24 months). The study intervention consists of blood samples. At each visit, 10 mL of blood will be collected, and additional blood samples (20 mL per visit) will be taken from a subgroup of participants.
Age
18–any
Sex
ALL
Healthy volunteers
Accepted
You may be eligible if
Any person aged 18 years old or over at the time of giving informed consent, of any gender
Participant received the MVA-BN or LC16m8 mpox vaccine as part of the national vaccination campaign
Participant has the capacity and willingness to give informed written consent
Participant agrees to adhere to the study's follow-up schedule